In vitro modeling accurately predicts cardiac lead fracture at 10 years

Area of Science:

• Biomedical Engineering
• Medical Device Development
• Cardiovascular Technology

Background:

• Cardiac lead fractures pose a significant risk to patients with implantable cardioverter-defibrillators (ICDs).
• Differentiating between high-performing and low-performing lead designs is crucial for improving patient outcomes and guiding future device innovation.
• Existing methods for evaluating lead durability may not fully capture real-world performance complexities.

Purpose of the Study:

• To develop and demonstrate a predictive model for cardiac lead fracture.
• To validate the model's predictions against observed 10-year fracture-free survival data for ICD leads.
• To establish a tool that can aid in the development of more robust and reliable cardiac lead technologies.

Main Methods:

• The predictive model integrates in vivo patient data, in vitro conductor fatigue test results, and statistical simulations.
• Model validation involved comparing predicted fracture-free survival with clinical performance data from specific Medtronic ICD lead models (Sprint Fidelis 6931, 6949, and Quattro 6947).
• Analysis focused on fracture-free survival rates and model accuracy, including average error calculations.

Main Results:

• Modeled fracture-free survival for the Quattro lead exceeded 97%, outperforming the Fidelis leads (<94%).
• The model's predictions closely aligned with observed clinical fracture-free survival data.
• The developed model demonstrated a low average error of 0.3% (SD 1.2%) when compared to real-world performance.

Conclusions:

• The developed model effectively predicts cardiac lead fracture-free survival.
• The model's accuracy, validated against clinical field data, supports its utility in assessing lead performance.
• This predictive tool, combining in vivo and in vitro data, can significantly contribute to the future design and development of safer ICD leads.